Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids
Recruitment status was Active, not recruiting
Procedure: Laparoscopic bilateral occlusion of uterine artery
Procedure: Radiological embolization (UFE)
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Randomized Trial Comparing Laparoscopic Bilateral Occlusion of Uterine Vessels to Uterine Fibroid Embolization for the Treatment of Symptomatic Uterine Fibroids|
- Reduction of menstrual bleeding six months after treatment measured by PBAC
- Patient assessment of symptom reduction including menorrhagia and bulk symptoms
- postoperative pain
- recovering time
- secondary interventions
- Reduction in fibroids and uterus size measured by ultrasonography and MRI
|Study Start Date:||December 2000|
|Estimated Study Completion Date:||April 2010|
Uterine fibroid embolization (UFE)has become an alternative to hysterectomy for women with symptoms of uterine fibroids.Follow up studies of this new method have reported relief of menstrual bleeding by 85-90 % of the patients six to twelve months after treatment.Other studies have suggested laparoscopic bilateral occlusion of uterine arteries as an equal effective alternative, but to our knowledge there is no randomized studies published.
Patients recruitment : Women with symptoms of uterine fibroids referred to the clinic,who express a desire to avoid hysterectomy.
Study hypothesis: Laparoscopic occlusion of uterine vessels and UFE have equal effect on bleeding symptoms.
Gynecological examination, ultrasonography and magnetic resonance imaging (MRI) are performed preoperatively and after 1,3 and 6 months. Clinical follow up is planned after 1,3,6,12,24,36 and 60 months.A validated bleeding chard, Pictorial Blood Assessment Chart(PBAC)is filled in by the participants during the last menstruation period before treatment and before each control. A standardized questionnaire to assess the bleeding amount,pressure symptoms, pain, adverse events, other complains and patients satisfaction is also used.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00277680
|Ullevål University Hospital|
|Oslo, Norway, 0407|
|Study Director:||Olav Istre, MD,PhD||Ullevål University Hospital, Dept.of Obstetrics and Gynecology|
|Principal Investigator:||Kirsten Hald, MD||Ullevål University Hospital, Dept of Obstetrics and Gynecology|
|Study Chair:||Nils-Einar Kløw, MD,PhD||Ullevaal University Hospital|